NDA submitted for Loramyc, an antifungal for oropharyngeal candidiasis

Strativa (a division of Par Pharmaceuticals) and BioAlliance Pharma announced the submission of a New Drug Application (NDA) to the FDA for Loramyc (miconazole Lauriad).  If approved, Strativa could launch Loramyc in the second half of 2010.

Loramyc 50mg is a mucoadhesive buccal tablet for the treatment of oropharyngeal candidiasis.

For more information call (201) 802-4000 or visit www.strativapharma.com